Comprehensive ReviewInfectious Complications in Patients With Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum of Infection, and Approaches to Prophylaxis
References (43)
- et al.
Infectious complications of chronic lymphocytic leukemia
Semin Oncol
(2006) - et al.
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: A systematic review and meta-analysis
Cancer Treat Rev
(2006) - et al.
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
Blood
(2001) - et al.
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
Blood
(2006) - et al.
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712)
Blood
(2003) - et al.
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial
Blood
(2000) - et al.
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
Blood
(2002) - et al.
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
Blood
(2003) - et al.
Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab
Clin Lymphoma Myeloma
(2006) Morrison. Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia
Hematology
(2007)
Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status
Leuk Lymphoma
The status on immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia
Cancer
Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia and multiple myeloma
Blood
Infectious and immunosuppressive complications of purine analog therapy
J Clin Oncol
Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup study Cancer and Leukemia Group B 9011
J Clin Oncol
Infections in patients with chronic lymphocytic leukemia treated with fludarabine
Ann Intern Med
Disease activity and pretreatment, rather than hypogammaglobulinemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukemia
Br J Haematol
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
J Clin Oncol
Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL) Polish multicentre study
Leuk Lymphoma
Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network
J Clin Oncol
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
J Clin Oncol
Cited by (104)
Vaccinations in patients with chronic lymphocytic leukemia
2024, Seminars in HematologyCharacteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: A multi-center retrospective study in Hubei, China
2021, BreastCitation Excerpt :Only one patient had grade 3–4 leucopenia (<2.0 G/L) according to the CTCAE grading classification and none had grade 3–4 neutropenia (<1.0 G/L), preventing any inclusion of the values in the uni- or multivariate analyses. Neutropenia has been linked to the chemotherapy effects of myelosuppression [27–29], which in turn worsens the immune condition. Additionally, immunosuppression by chemotherapy possibly prolongs the time of viral shedding [30], which provides an explanation for our study, indicating that chemotherapy within 7 days may have led to myelosuppression and secondary infection, resulting in an aggravated illness and poor COVID-19 outcomes.
Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
2021, Hematology/Oncology Clinics of North AmericaCitation Excerpt :Other sites of infection in order of frequency are the upper respiratory tract, genitourinary tract, blood, skin, and soft tissue, gastrointestinal tract, and central nervous system.37 The severity of hypogammaglobulinemia correlates with infection risk.38 IgG levels less than 3 g/L confer a high risk of infections and depressed IgA was associated with inferior survival independent of disease stage.39,40
Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations
2020, Journal of Allergy and Clinical ImmunologyClinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
2020, The Lancet OncologyCitation Excerpt :They are often immunosuppressed because of their underlying illness, poor nutrition, and treatment-related side-effects. Therefore, they are at increased risk of opportunistic infections, developing severe complications, requiring admission to an intensive care unit (ICU), or even death.6–9 Liang and colleagues10 analysed data from 18 patients with cancer, from a sample of 1590 patients with COVID-19, and found a higher risk of COVID-19 and poorer outcomes in patients with cancer than in those without.
Immunoglobulin replacement to prevent infections in people with haematological malignancies and haematopoietic stem cell transplantation
2024, Cochrane Database of Systematic Reviews
This summary may include the discussion of investigational and/or unlabeled uses of drugs and/or devices that may not be approved by the FDA.
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1557-9190, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.